Abstract
Objective: In the present study, we are reporting the clinical profile; and outcomes of COVID-19 in patients with hematological malignancy at tertiary care hospitals. Methods: Data from laboratory-confirmed 40 COVID-19 patients diagnosed between January 1, 2021 and July 31, 2021, were analyzed retrospectively. All COVID-19 patients with hematological malignancy (n=40) were included in the study. Results: In the present study, a total of 40 patients were included. Of 40, 25 (62.5%) were males, and 15 (37.5%) were females. The median age in this study was 43 years (Range, 8–70). Of these 40 patients, acute myeloid leukemia was the most common malignancy 11 (27.5%), followed by acute lymphoblastic leukemia 9 (22.5%) than non-Hodgkin lymphoma 5 (12.5%), plasma cell dyscrasia 4 (10%), chronic myeloid leukemia 4 (10%), chronic lymphocytic leukemia 3 (7.5%), acute promyelocytic leukemia 2 (5%), chronic myelomonocytic leukemia 2 (5%). Mean hemoglobin was (8.04 g/dl), white blood cell count was (10.14×109/l), platelet count was (77.7×109/l) creatinine was (0.86 mg/dl), bilirubin was (1.24 mg/dl). The overall case-fatality rate was 8 (22.5%). Conclusion: Patients with hematological malignancy are immunocompromised, and our study reveals that there is an increased case fatality rate among these patients. Hence, physicians should be aggressive in the management of COVID‐19 patients with hematological malignancy.
Highlights
IntroductionThe majority of Coronaviruses (CoVs) are pathogenic to humans, but very rarely cause serious infections
Hypertension was the most frequent comorbid disease associated with COVID-19 patients with hematological malignancy and seen in 8 (20%) patients followed by ischemic heart disease in 4 (10%) patients
The most common blood cancer in our study was acute myeloid leukemia followed by acute lymphoblastic leukemia, non-Hodgkin lymphoma
Summary
The majority of Coronaviruses (CoVs) are pathogenic to humans, but very rarely cause serious infections. A bunch of pneumonia cases with an unidentified cause was observed in Wuhan, China (December 2019). These pulmonary infection cases were caused by the SARS-CoV-2 [1]. The severity and mortality of disease are higher in those with comorbidities, active malignancy, or old age. Patients with malignancy are at high risk of severe disease. There are only limited data about COVID-19 in patients with blood cancer, and the majority of this literature is based on a case report, case series. In the present study, we are reporting the outcome of COVID-19 patients in hematological malignancies
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Asian Journal of Pharmaceutical and Clinical Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
